Eltrombopag is the world's first small molecule non peptide thrombopoietin receptor (TPO-R) agonist approved by the US Food and Drug Administration (FDA). It was approved by the FDA in 2008 for the treatment of idiopathic thrombocytopenic purpura (ITP).
Eltrombopag, as the first approved small molecule non peptide TPO-R agonist, occupies an important position in the drug market. It, together with other similar products such as Avatrombopag and Lusutotrombopag, constitutes an important drug choice for the treatment of thrombocytopenia.
To explore the price of eltrombopag and its role in the treatment of specific diseases to provide a reference for patients.How much is a box of eltrombopaThe price of eltrombopag a···【more】
Article source:Lucius LaosRelease date:2025-03-13Recommended:86
In the healthcare sector, the price of medicines is an aspect of great concern for patients and their families.How much do the different versions of eltrombopag cost?Knowing how th···【more】
Article source:Lucius LaosRelease date:2025-03-13Recommended:65
Variety and availability of medications is an important consideration for both patients and healthcare providers, as it directly impacts treatment selection and efficacy.How many v···【more】
Article source:Lucius LaosRelease date:2025-03-12Recommended:73
Eltrombopag is a drug used to treat specific blood disorders, and its clinical application has brought new hope to many patients.What kind of medicine is eltrombopag?Eltrombopag is···【more】
Article source:Lucius LaosRelease date:2025-03-12Recommended:87
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: